{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Activity+matched+control", "query": { "intervention": "Activity matched control" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1410, "total_pages": 141, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Activity+matched+control&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T23:01:05.985Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05180708", "title": "A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pachyonychia Congenita" ], "interventions": [ { "name": "QTORIN 3.9% rapamycin anhydrous gel", "type": "DRUG" }, { "name": "Vehicle", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Palvella Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2021-11-29", "completion_date": "2023-06-30", "has_results": false, "last_update_posted_date": "2024-08-29", "last_synced_at": "2026-09-08T23:01:05.985Z", "location_count": 7, "location_summary": "Palo Alto, California • New Haven, Connecticut • Orange Park, Florida + 4 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orange Park", "state": "Florida" }, { "city": "Fridley", "state": "Minnesota" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05180708" }, { "nct_id": "NCT04181762", "title": "Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lupus Nephritis" ], "interventions": [ { "name": "secukinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 275, "start_date": "2020-07-07", "completion_date": "2023-09-13", "has_results": true, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-09-08T23:01:05.985Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Fontana, California • Los Angeles, California + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fontana", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aventura", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04181762" }, { "nct_id": "NCT00717262", "title": "Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "HQK-1001", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HemaQuest Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 41, "start_date": "2008-05", "completion_date": "2008-09", "has_results": false, "last_update_posted_date": "2009-01-16", "last_synced_at": "2026-09-08T23:01:05.985Z", "location_count": 1, "location_summary": "Tacoma, Washington", "locations": [ { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00717262" }, { "nct_id": "NCT03310359", "title": "Clinical Trial of Anti-oxidant Astaxanthin in Insulin-resistant Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metabolic Syndrome X" ], "interventions": [ { "name": "Astaxanthin", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 34, "start_date": "2016-07", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2024-01-23", "last_synced_at": "2026-09-08T23:01:05.985Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03310359" }, { "nct_id": "NCT03656510", "title": "Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Respiratory Syncytial Virus Infections" ], "interventions": [ { "name": "JNJ-53718678", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "28 Days", "maximum_age": "3 Years", "sex": "ALL", "summary": "28 Days to 3 Years" }, "enrollment_count": 246, "start_date": "2018-11-29", "completion_date": "2022-04-18", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-09-08T23:01:05.985Z", "location_count": 14, "location_summary": "Madera, California • Ventura, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Madera", "state": "California" }, { "city": "Ventura", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Blackfoot", "state": "Idaho" }, { "city": "Nampa", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT03656510" }, { "nct_id": "NCT01552343", "title": "Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Nocturia" ], "interventions": [ { "name": "Desmopressin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ferring Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2012-03", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2017-07-11", "last_synced_at": "2026-09-08T23:01:05.985Z", "location_count": 10, "location_summary": "Aventura, Florida • DeLand, Florida • Peoria, Illinois + 6 more", "locations": [ { "city": "Aventura", "state": "Florida" }, { "city": "DeLand", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Springfield", "state": "Massachusetts" }, { "city": "Kalamazoo", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01552343" }, { "nct_id": "NCT05478278", "title": "An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "QTc Interval", "Pharmacokinetics" ], "interventions": [ { "name": "Psilocybin", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Micro-Crystalline Cellulose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Usona Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2022-06-22", "completion_date": "2023-08-09", "has_results": false, "last_update_posted_date": "2023-08-15", "last_synced_at": "2026-09-08T23:01:05.985Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05478278" }, { "nct_id": "NCT04433546", "title": "Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Respiratory Distress Syndrome", "Coronavirus", "Hypoxic Respiratory Failure", "Hypoxemic Respiratory Failure", "Respiratory Complication", "Respiratory Insufficiency", "Cardiac Dysfunction", "Pneumonia", "Pulmonary Edema", "Pulmonary Inflammation", "Respiratory Failure", "Cytokine Storm", "COVID 19", "SARS-CoV-2", "Cardiac Event", "Cardiac Complication", "Cardiac Failure", "Cardiac Infarct" ], "interventions": [ { "name": "Pemziviptadil (PB1046)", "type": "DRUG" }, { "name": "Low Dose (10 mg) Control", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PhaseBio Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 54, "start_date": "2020-07-15", "completion_date": "2020-12-02", "has_results": false, "last_update_posted_date": "2020-12-11", "last_synced_at": "2026-09-08T23:01:05.985Z", "location_count": 4, "location_summary": "Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04433546" }, { "nct_id": "NCT02957461", "title": "Validation of Brain Function Assessment Algorithm for mTBI/Concussion in College Athletes", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Brain Injuries, Traumatic", "Concussion, Mild", "Concussion, Brain", "Concussion, Severe", "Concussion, Intermediate" ], "interventions": [ { "name": "BrainScope Ahead 200iD", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "BrainScope Company, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "18 Years to 25 Years" }, "enrollment_count": 420, "start_date": "2017-02-03", "completion_date": "2018-03-02", "has_results": false, "last_update_posted_date": "2019-05-23", "last_synced_at": "2026-09-08T23:01:05.985Z", "location_count": 8, "location_summary": "Fayetteville, Arkansas • Storrs, Connecticut • Tampa, Florida + 5 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Storrs", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "East Lansing", "state": "Michigan" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02957461" }, { "nct_id": "NCT01962961", "title": "N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV", "Endothelial Dysfunction", "Oxidative Stress" ], "interventions": [ { "name": "PharmaNAC (N-acetylcysteine)", "type": "DIETARY_SUPPLEMENT" }, { "name": "Matching placebo", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 24, "start_date": "2013-10", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2016-02-08", "last_synced_at": "2026-09-08T23:01:05.985Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01962961" } ] }